![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
FJ Ehlert
Department of Pharmacology, College of Medicine, University of California, Irvine 92717.
The theoretical basis for using radioligand binding and pharmacological techniques to estimate the dissociation constants of drugs which interact allosterically with receptors is described. This theory predicts that an allosteric ligand changes the affinity of another ligand which binds at the primary recognition site on the receptor complex without affecting the binding capacity of the primary ligand. The magnitude of this effect depends on the amount of cooperativity (positive or negative) between the binding of ligands at the allosteric and primary recognition sites. It is possible to estimate the dissociation constant of an allosteric ligand by measuring its effect on the binding of a radioligand at a fixed concentration. In this situation, the dissociation constant of the allosteric ligand can be calculated from the concentration of ligand which causes half of its maximal effect on radioligand binding. The effects of an allosteric ligand on the pharmacological responses to an agonist can be attributed to changes in affinity and intrinsic efficacy of the agonist-receptor complex. If the agonist used in the pharmacological experiments has a large receptor reserve, or if the allosteric ligand only influences the affinity of the agonist, then the dissociation constant of the allosteric ligand can be calculated from the results of experiments in which the concentration of agonist required for half-maximal response (EC50) is measured in the presence of various concentrations of the allosteric ligand. If the agonist used in the pharmacological experiments is a partial agonist with little receptor reserve, then the shift in the EC50 of the agonist caused by the allosteric ligand may be dependent on the affinity of the agonist.
This article has been cited by other articles:
|
|
 |
|
  V. Nawaratne, K. Leach, N. Suratman, R. E. Loiacono, C. C. Felder, B. N. Armbruster, B. L. Roth, P. M. Sexton, and A. Christopoulos New Insights into the Function of M4 Muscarinic Acetylcholine Receptors Gained Using a Novel Allosteric Modulator and a DREADD (Designer Receptor Exclusively Activated by a Designer Drug) Mol. Pharmacol., October 1, 2008; 74(4): 1119 - 1131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. A. Avlani, D. J. McLoughlin, P. M. Sexton, and A. Christopoulos The Impact of Orthosteric Radioligand Depletion on the Quantification of Allosteric Modulator Interactions J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 927 - 934. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Ehlert and M. T. Griffin Two-State Models and the Analysis of the Allosteric Effect of Gallamine at the M2 Muscarinic Receptor J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 1039 - 1060. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Langmead Screening for Positive Allosteric Modulators: Assessment of Modulator Concentration-Response Curves as a Screening Paradigm J Biomol Screen, August 1, 2007; 12(5): 668 - 676. [Abstract] [PDF]
|
|
|
|
|
|
T. Steinfeld, M. Mammen, J. A. M. Smith, R. D. Wilson, and J. R. Jasper A Novel Multivalent Ligand That Bridges the Allosteric and Orthosteric Binding Sites of the M2 Muscarinic Receptor Mol. Pharmacol., August 1, 2007; 72(2): 291 - 302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. T. May, V. A. Avlani, C. J. Langmead, H. J. Herdon, M. D. Wood, P. M. Sexton, and A. Christopoulos Structure-Function Studies of Allosteric Agonism at M2 Muscarinic Acetylcholine Receptors Mol. Pharmacol., August 1, 2007; 72(2): 463 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Griffin, K. W. Figueroa, S. Liller, and F. J. Ehlert Estimation of Agonist Activity at G Protein-Coupled Receptors: Analysis of M2 Muscarinic Receptor Signaling through Gi/o,Gs, and G15 J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 1193 - 1207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. Rothman, D. L. Murphy, H. Xu, J. A. Godin, C. M. Dersch, J. S. Partilla, K. Tidgewell, M. Schmidt, and T. E. Prisinzano Salvinorin A: Allosteric Interactions at the {micro}-Opioid Receptor J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 801 - 810. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kenakin, S. Jenkinson, and C. Watson Determining the Potency and Molecular Mechanism of Action of Insurmountable Antagonists J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 710 - 723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Lanzafame, P. M. Sexton, and A. Christopoulos Interaction Studies of Multiple Binding Sites on M4 Muscarinic Acetylcholine Receptors Mol. Pharmacol., August 1, 2006; 70(2): 736 - 746. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Prilla, J. Schrobang, J. Ellis, H.-D. Holtje, and K. Mohr Allosteric Interactions with Muscarinic Acetylcholine Receptors: Complex Role of the Conserved Tryptophan M2422Trp in a Critical Cluster of Amino Acids for Baseline Affinity, Subtype Selectivity, and Cooperativity Mol. Pharmacol., July 1, 2006; 70(1): 181 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Fruchart-Gaillard, G. Mourier, C. Marquer, A. Menez, and D. Servent Identification of Various Allosteric Interaction Sites on M1 Muscarinic Receptor Using 125I-Met35-Oxidized Muscarinic Toxin 7 Mol. Pharmacol., May 1, 2006; 69(5): 1641 - 1651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Langmead, V. A. H. Fry, I. T. Forbes, C. L. Branch, A. Christopoulos, M. D. Wood, and H. J. Herdon Probing the Molecular Mechanism of Interaction between 4-n-Butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the Muscarinic M1 Receptor: Direct Pharmacological Evidence That AC-42 Is an Allosteric Agonist Mol. Pharmacol., January 1, 2006; 69(1): 236 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Ehlert Analysis of Allosterism in Functional Assays J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 740 - 754. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Price, G. L. Baillie, A. Thomas, L. A. Stevenson, M. Easson, R. Goodwin, A. McLean, L. McIntosh, G. Goodwin, G. Walker, et al. Allosteric Modulation of the Cannabinoid CB1 Receptor Mol. Pharmacol., November 1, 2005; 68(5): 1484 - 1495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Jakubik, A. Krejci, and V. Dolezal Asparagine, Valine, and Threonine in the Third Extracellular Loop of Muscarinic Receptor Have Essential Roles in the Positive Cooperativity of Strychnine-Like Allosteric Modulators J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 688 - 696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Watson, S. Jenkinson, W. Kazmierski, and T. Kenakin The CCR5 Receptor-Based Mechanism of Action of 873140, a Potent Allosteric Noncompetitive HIV Entry Inhibitor Mol. Pharmacol., April 1, 2005; 67(4): 1268 - 1282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. T. May, Y. Lin, P. M. Sexton, and A. Christopoulos Regulation of M2 Muscarinic Acetylcholine Receptor Expression and Signaling by Prolonged Exposure to Allosteric Modulators J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 382 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kenakin Allosteric Modulators: The New Generation of Receptor Antagonist Mol. Interv., August 1, 2004; 4(4): 222 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Lanzafame and A. Christopoulos Investigation of the Interaction of a Putative Allosteric Modulator, N-(2,3-Diphenyl-1,2,4-thiadiazole-5-(2H)-ylidene) Methanamine Hydrobromide (SCH-202676), with M1 Muscarinic Acetylcholine Receptors J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 830 - 837. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Selz, A. J. Mandell, M. F. Shlesinger, V. Arcuragi, and M. J. Owens Designing Human m1 Muscarinic Receptor-Targeted Hydrophobic Eigenmode Matched Peptides as Functional Modulators Biophys. J., March 1, 2004; 86(3): 1308 - 1331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Avlani, L. T. May, P. M. Sexton, and A. Christopoulos Application of a Kinetic Model to the Apparently Complex Behavior of Negative and Positive Allosteric Modulators of Muscarinic Acetylcholine Receptors J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 1062 - 1072. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lazareno, V. Dolezal, A. Popham, and N. J. M. Birdsall Thiochrome Enhances Acetylcholine Affinity at Muscarinic M4 Receptors: Receptor Subtype Selectivity via Cooperativity Rather than Affinity Mol. Pharmacol., January 1, 2004; 65(1): 257 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. O'Brien, W. Lemaire, T.-B. Chen, R. S. L. Chang, M. A. Jacobson, S. N. Ha, C. W. Lindsley, H. J. Schaffhauser, C. Sur, D. J. Pettibone, et al. A Family of Highly Selective Allosteric Modulators of the Metabotropic Glutamate Receptor Subtype 5 Mol. Pharmacol., September 1, 2003; 64(3): 731 - 740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. J. Hoare, S. K. Sullivan, N. Ling, P. D. Crowe, and D. E. Grigoriadis Mechanism of Corticotropin-Releasing Factor Type I Receptor Regulation by Nonpeptide Antagonists Mol. Pharmacol., March 1, 2003; 63(3): 751 - 765. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Christopoulos and T. Kenakin G Protein-Coupled Receptor Allosterism and Complexing Pharmacol. Rev., June 1, 2002; 54(2): 323 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gillard, C. Van Der Perren, N. Moguilevsky, R. Massingham, and P. Chatelain Binding Characteristics of Cetirizine and Levocetirizine to Human H1 Histamine Receptors: Contribution of Lys191 and Thr194 Mol. Pharmacol., February 1, 2002; 61(2): 391 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Hall Modeling the Functional Effects of Allosteric Modulators at Pharmacological Receptors: An Extension of the Two-State Model of Receptor Activation Mol. Pharmacol., April 13, 2001; 58(6): 1412 - 1423. [Abstract] [Full Text]
|
|
|
|
|
|
V. Blandin, P. Vigne, J. P. Breittmayer, and C. Frelin Allosteric Inhibition of Endothelin ETA Receptors by 3,5-Dibromosalicylic Acid Mol. Pharmacol., April 13, 2001; 58(6): 1461 - 1469. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. M. Jose, G. A. Soukup, and R. R. Breaker Cooperative binding of effectors by an allosteric ribozyme Nucleic Acids Res., April 1, 2001; 29(7): 1631 - 1637. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lazareno, A. Popham, and N. J. M. Birdsall Allosteric Interactions of Staurosporine and Other Indolocarbazoles with N-[methyl-3H]Scopolamine and Acetylcholine at Muscarinic Receptor Subtypes: Identification of a Second Allosteric Site Mol. Pharmacol., July 1, 2000; 58(1): 194 - 207. [Abstract] [Full Text]
|
|
|
|
|
|
R. A. Leppik, A. Mynett, S. Lazareno, and N. J. M. Birdsall Allosteric Interactions between the Antagonist Prazosin and Amiloride Analogs at the Human alpha 1A-Adrenergic Receptor Mol. Pharmacol., March 1, 2000; 57(3): 436 - 445. [Abstract] [Full Text]
|
|
|
|
|
|
J. A. Schetz, A. Chu, and D. R. Sibley Zinc Modulates Antagonist Interactions with D2-Like Dopamine Receptors through Distinct Molecular Mechanisms J. Pharmacol. Exp. Ther., May 1, 1999; 289(2): 956 - 964. [Abstract] [Full Text]
|
|
|
|
|
|
S. Horio, T. Nagare, Y. Ishida, and H. Moritoki Effects of Local Anesthetics on Acetylcholine-Induced Desensitization of Guinea Pig Ileal Longitudinal Muscle J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 221 - 227. [Abstract] [Full Text]
|
|
|
|
|
|
C. Xu and M. E. A. Reith WIN 35,428 and Mazindol Are Mutually Exclusive in Binding to the Cloned Human Dopamine Transporter J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 920 - 927. [Abstract] [Full Text]
|
|
|
|
|
|
A. Lanzafame, A. Christopoulos, and F. Mitchelson Three Allosteric Modulators Act at a Common Site, Distinct from that of Competitive Antagonists, at Muscarinic Acetylcholine M2 Receptors J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 278 - 285. [Abstract] [Full Text]
|
|
|
|
|
|
M. Hagiwara, S. Adachi-Akahane, and T. Nagao High-Affinity Binding of DTZ323, a Novel Derivative of Diltiazem, to Rabbit Skeletal Muscle L-type Ca++ Channels J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 173 - 179. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. R. J. Hoare, T. J. Gardella, and T. B. Usdin Evaluating the Signal Transduction Mechanism of the Parathyroid Hormone 1 Receptor. EFFECT OF RECEPTOR-G-PROTEIN INTERACTION ON THE LIGAND BINDING MECHANISM AND RECEPTOR CONFORMATION J. Biol. Chem., March 9, 2001; 276(11): 7741 - 7753. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
